Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Otolaryngol Head Neck Surg. 2023 Jul;169(1):120-128. doi: 10.1002/ohn.229. Epub 2023 Jan 29.
This study sought to validate alternative pain management strategies that can reduce reliance on opioids for postoperative pain management in otology.
Prospective cohort study.
Single tertiary-care facility.
Adult patients who underwent outpatient otologic surgery from September 2021 to July 2022 were randomized into treatment cohorts. The opioid monotherapy cohort received a standard opioid prescription. The multimodal analgesia cohort received the same opioid prescription, prescriptions for acetaminophen and naproxen, and additional pain management education with a flyer on discharge. All patients completed a questionnaire 1 week after surgery to evaluate opioid usage and pain scores.
Eighty-six patients completed the study. The opioid monotherapy cohort (n = 42) and multimodal analgesia cohort (n = 44) were prescribed an average of 42.1 ± 20.4 morphine milligram equivalents (MME) and 38.4 ± 5.7 MME, respectively (p = 0.373). Four patients (9.52%) in the opioid monotherapy cohort required opioid refills compared to 1 patient (2.27%) in the multimodal analgesia cohort (p = 0.156). Multivariate analysis demonstrated that the multimodal analgesia cohort consumed significantly fewer opioids on average than the opioid monotherapy cohort (11.9 ± 15.9 MME vs 22.8 ± 28.0 MME, respectively). There were no significant differences in postoperative rehospitalizations (p = 0.317) or Emergency Department visits (p = 0.150). Pain scores on the day of surgery, postoperative day (POD) 1, POD3, and POD7 were not significantly different between cohorts (p = 0.395, 0.896, 0.844, 0.765, respectively).
The addition of patient education, acetaminophen, and naproxen to postoperative opioid prescriptions significantly reduced opioid consumption without affecting pain scores, refill rates, or complication rates after otologic surgery.
本研究旨在验证替代疼痛管理策略,以减少耳科学术后对阿片类药物的依赖。
前瞻性队列研究。
单一的三级保健机构。
2021 年 9 月至 2022 年 7 月接受门诊耳科手术的成年患者被随机分为治疗组。阿片类药物单药治疗组接受标准阿片类药物处方。多模式镇痛组除了给予相同的阿片类药物处方、对乙酰氨基酚和萘普生处方外,还在出院时给予额外的疼痛管理教育,包括一份传单。所有患者在术后 1 周完成问卷,评估阿片类药物使用情况和疼痛评分。
86 例患者完成了研究。阿片类药物单药治疗组(n=42)和多模式镇痛组(n=44)分别开了平均 42.1±20.4 吗啡毫克当量(MME)和 38.4±5.7 MME(p=0.373)。阿片类药物单药治疗组中有 4 例(9.52%)患者需要阿片类药物补充,而多模式镇痛组中只有 1 例(2.27%)(p=0.156)。多变量分析表明,多模式镇痛组平均消耗的阿片类药物明显少于阿片类药物单药治疗组(分别为 11.9±15.9 MME 和 22.8±28.0 MME)。两组患者术后再住院率(p=0.317)或急诊科就诊率(p=0.150)无显著差异。手术当天、术后第 1 天(POD1)、第 3 天(POD3)和第 7 天(POD7)的疼痛评分在两组之间无显著差异(p=0.395、0.896、0.844、0.765)。
在术后阿片类药物处方中添加患者教育、对乙酰氨基酚和萘普生可显著减少阿片类药物的消耗,而不影响疼痛评分、补充率或耳科手术后的并发症发生率。